Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122466 · ClinicalTrials.gov registry record
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
A clinical trial of Metastatic Pancreatic Cancer, sponsored by Northwell Health.
- Active
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT07122466: Active study of Metastatic Pancreatic Cancer, sponsored by Northwell Health.
NCT07122466 is a study of Metastatic Pancreatic Cancer that is active but no longer recruiting, run by Northwell Health. The registered enrollment target is 24 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07122466, a study of Metastatic Pancreatic Cancer, is active but no longer recruiting, sponsored by Northwell Health.
- ACTIVE NOT RECRUITING
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
Primary Outcome
Compare first follow-up imaging assessment at 2 months with tumor response as assessed by ctDNA level change from baseline
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)
Study Locations (1)
New York
- Zuckerberg Cancer Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2025-09 |
What the registry record for NCT07122466 still lists
NCT07122466 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) is the first listed.
NCT07122466 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07122466 about?
NCT07122466 is a clinical study titled "Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy". This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the st...
What is the current status of trial NCT07122466?
This trial is currently active not recruiting. The enrollment target is 24 participants. The study started on 2023-05-22. Estimated completion is 2025-09.
What conditions does trial NCT07122466 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT07122466?
The interventions under investigation include: Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07122466?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122466 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07122466's enrollment target sits among peer trials
24 28th of 32 higher than 4 of 32 other Metastatic Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 1
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI